Wish to invest in Estonia? Read more about the opportunities Estonia offers in e-Health here and send us an e-Consulting request to get more detailed information.
Startups are not just cool or good for the economy. Many save lives, and Estonia has a particularly impressive run of e-health innovations recently. Recently, UK-Estonian HealthTech startup Lifeyear has raised funding to tackle the cardiovascular disease crisis, which causes 1 in 3 deaths globally. The company secured €2.8M in funding to launch its remote patient management platform for cardiovascular care.
In its home market of the UK, it will tackle an urgent problem, with over 418,000 people in the national cardiac waiting lists and cardiovascular disease projected to surge. Instead of a traditional approach, Lifeyear’s platform delivers smartphone-enabled heart care directly to patients’ homes. For patients, this means easier access to personalised care with fewer hospital visits and shorter waiting times. Clinicians benefit from simplified remote monitoring and medication management, allowing them to focus their attention on high-priority cases.
The team is up to the challenge. Dr. Eleanor Wicks serves as Chief Medical Officer, bringing over 20 years of NHS experience as a cardiologist at Barts Health NHS Trust and Oxford University Hospitals. CEO Siim Saare and CTO Timo Mitt contribute Estonian tech expertise.
Lifeyear co-founders Siim Saare, Dr Eleanor Wicks and Timo Mitt
The new investment includes €1.5 million in Estonian government DeepTech grants alongside €1.3M from venture capital funds, including Verge HealthTech Fund, Tilia Impact Ventures, and PurposeTech.
Oxford University Hospitals NHS Foundation Trust has also become a shareholder, validating the platform’s potential through their NHS Market Access Accelerator program. “Lifeyear’s platform aligns with our mission to deliver innovative, patient-centred care. Their focus on digital cardiovascular care addresses a critical need in the NHS,” said Fred Kemp, Head of Commercial Data and Innovation at OUH. In Estonia, the company partners with University of Tartu, and Estonian Genome Center.
“This funding is a pivotal step in our mission to reduce the global cardiovascular disease burden. We’re focused on redefining how cardiovascular care is delivered, starting with patients who need it the most,” explains Siim Saare.
